Holen Sie sich die Stockscreener-App
0.19
75.51%
-0.545
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia
Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Candel Therapeutics Announces Pricing of Public Offering - The Manila Times
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street - The Joplin Globe
Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat
TMC the metals (NASDAQ:TMC) vs. Canadian Zeolite (OTCMKTS:IZCFF) Critical Review - Defense World
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
HCA Healthcare (NYSE:HCA) Shares Gap Up After Earnings Beat - Defense World
Boku (LON:BOKU) Insider Jonathan Peter Prideaux Sells 325,000 Shares of Stock - Defense World
Huge Waltham lab lease fuels work on potential Dravet syndrome drug - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat
More cash flows into biotechs during conference week: Finance Report - biocentury.com
Aptevo Therapeutics (NASDAQ: APVO) seeks OK for $60M SEPA share sales - Stock Titan
Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn
Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - MSN
Early ZYCUBO treatment cut death risk nearly 80% in children with Menkes - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Mersana Therapeutics (NASDAQ:MRSN) Upgraded at Wall Street Zen - MarketBeat
Karyopharm (NASDAQ: KPTI) plans big share authorization increase to fund 2026 trials - stocktitan.net
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - Улправда
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - ADVFN
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting - ADVFN
Avenue Therapeutics (ATXI) investors reelect six directors and ratify KPMG for 2025 - Stock Titan
Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Australia
CRX is an intrinsic suppressor of epithelial‒mesenchymal transition in retinal pigment epithelial cells: a promising therapeutic avenue for subretinal fibrosis | Cell Death & Disease - Nature
ATXI: All directors were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
ATXI: All director nominees were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen - MarketBeat
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - TechStock²
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison - Defense World
The Philippines - AstraZeneca
Avenue Therapeutics, Inc.Common Stock (NQ: ATXI - FinancialContent
Form 424B3 Ovid Therapeutics Inc. - StreetInsider
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Axsome Therapeutics stock hits all-time high at 152.98 USD - Investing.com
Axsome Therapeutics stock hits all-time high at 152.98 USD By Investing.com - Investing.com Australia
Axsome Therapeutics (AXSM) Gets a Buy from Jefferies - The Globe and Mail
Avenue Therapeutics (ATXI) plans resale of 731,061 warrant-linked shares - Stock Titan
[RW] AVENUE THERAPEUTICS, INC. SEC Filing - Stock Titan
Fortress Biotech (Nasdaq: FBIO): FDA accepts Class 1 resubmission, CUTX-101 PDUFA Jan. 14, 2026 - Stock Titan
0.96%
0.13%
Kapitalisierung:
|
Volumen (24h):